CNSP - Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan cnspharma.com

The current EV/EBITDA chart, with a value of 0.00, highlights the risks of the single-product model of CNS Pharmaceuticals (CNSP), where business success depends on a single drug. Management is focused on glioblastoma therapy trials, maintaining data transparency while relying on fresh capital. Meanwhile, CNS Pharmaceuticals (CNSP) is monetizing an exclusive drug whose uniqueness and patent protection ensure sustained market demand.

CNS Pharmaceuticals Inc - Pangali EV/EBITDA CNSP (periode 23.11.2025 - 14.11.2026)

CNS Pharmaceuticals, Inc. - rincian analitis lan metrik utama (CNSP)

- rega saiki lan proyeksi nilai saham:

Rega saham CNS Pharmaceuticals|CNSP - Bagan rega target

- statistik kapitalisasi pasar:

Nilai pasar CNS Pharmaceuticals Inc|CNSP - Nilai Dipunlarasaken Utang lan Kas

- indikator nilai buku ekuitas:

Nilai Buku saben Saham CNS Pharmaceuticals|CNSP - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku cnspharma.com|CNSP - Gunggung Aset Perusahaan

- informasi babagan utang lan solvabilitas:

Utang marang Ekuitas CNS Pharmaceuticals|CNSP - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal CNS Pharmaceuticals Corp|CNSP - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku CNS Pharma|CNSP - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan CNS Pharmaceuticals|Indikator likuiditas cepet cnspharma.com

- rincian asil keuangan lan kelipatan valuasi:

CNSP - Bathi pungkasan|Bathi sing dikarepake CNS Pharmaceuticals|CNSP - Kapitalisasi marang bathi resik|Pangali Forward P/E CNS Pharmaceuticals, Inc.|CNSP - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA CNS Pharmaceuticals|CNSP - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan CNS Pharmaceuticals|CNSP - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan cnspharma.com|CNSP - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep CNS Pharmaceuticals

- data total pendapatan lan volume dodolan:

CNSP - Pendapatan lan volume dodolan|Prakiraan volume dodolan cnspharma.com|CNSP - Kapitalisasi marang pendapatan|Multiplikator Forward P/S CNS Pharmaceuticals Corp

Analisis kabeh metrik perusahaan:CNSP (CNS Pharmaceuticals, Inc.)

CNS Pharmaceuticals focuses on developing innovative drugs against glioblastoma, which makes the company dependent on external investments. The EV/EBITDA valuation trend reflects the ratio of the total enterprise value, including net debt, to operating profit before depreciation and amortization. A decline in this ratio on the chart signals a potential undervaluation of the asset, whereas a sharp increase indicates that quotes are overheating.

Analisis pesaing CNS Pharmaceuticals

Pangali EV/EBITDA SHPH (Shuttle Pharmaceuticals)